$19.98+1.94% 1DFinazon · prior-day close · Aug 17, 2026
Price · Chart
Our own end-of-day closes61 sessions
$22.5$12.520 May17 Aug
The line runs $16.29 on 20 May through $19.98 on 17 August, on a scale from $12.5 to $22.5. Days the market did not trade hold the previous close, flat.
The chart above plots the price of AVTX over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 61 sessions over that window: $16.29 on 20 May 2026 through $19.98 on 17 August 2026.
Market cap$1.1B
52-week range$8.92 – $24
Avg volume207.7K
Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 18, 2026
AVTX insider trades
SEC Form 4 · last 90 days · newest reported trade 11 Aug 2026
Open-market buys0
Open-market sells6
Net sold$216K
Non-trade filings14
DateInsiderTypeSharesValue
11 Aug 2026Riley JenniferChief Strategy OfficerSell2,655$52K
10 Aug 2026Doyle MittieChief Medical OfficerSell679$14K
27 Jul 2026Doyle MittieChief Medical OfficerSell1,000$20K
30 Jun 2026Doyle MittieChief Medical OfficerSell4,654$93K
23 Jun 2026Doyle MittieChief Medical OfficerSell1,450$26K
28 May 2026Doyle MittieChief Medical OfficerSell679$11K
Compensation mechanics
Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.
DateInsiderTypeSharesValue
10 Aug 2026Doyle MittieChief Medical OfficerOption exercise679$5K
27 Jul 2026Doyle MittieChief Medical OfficerOption exercise1,000$13K
30 Jun 2026Doyle MittieChief Medical OfficerOption exercise4,654$51K
23 Jun 2026Doyle MittieChief Medical OfficerOption exercise1,450$12K
10 Jun 2026VARKI PAULChief Legal OfficerTax withheld1,081$14K
10 Jun 2026Sullivan Christopher RyanChief Financial OfficerTax withheld138$2K
10 Jun 2026Doyle MittieChief Medical OfficerTax withheld1,084$14K
10 Jun 2026Riley JenniferChief Strategy OfficerTax withheld588$8K
28 May 2026Doyle MittieChief Medical OfficerOption exercise679$5K
21 May 2026NEIL GARRY ARTHURChief Executive OfficerAward100,200
21 May 2026VARKI PAULChief Legal OfficerAward24,300
21 May 2026Sullivan Christopher RyanChief Financial OfficerAward39,900
Showing the 12 most recent of 14 compensation filings in this window. The figures above count all of them.
AVTX reported financials
SEC EDGAR XBRL
AVTX reported revenue of $59K for the fiscal year ended 31 Dec 2025. Net income over the same period was −$78.3M.
FigureReportedPeriod
Revenue
$59K
31 Dec 2025 fiscal year
Net income
−$78.3M
31 Dec 2025 fiscal year
Diluted EPS
−$5.84
31 Dec 2025 fiscal year
Total assets
$490.8M
30 Jun 2026 at period end
Total equity
$448.7M
30 Jun 2026 at period end
Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
AVTX earnings
SEC EDGAR
DatePeriodEPSRevenue
30 Jun 2026Q2 2026$-0.83—
31 Mar 2026Q1 2026$-0.98—
31 Dec 2025FY 2025$-5.84—
30 Sep 2025Q3 2025$-2.19—
30 Jun 2025Q2 2025$-1.92—
31 Mar 2025Q1 2025$-1.25—
31 Dec 2024FY 2024$-20.91—
30 Sep 2024Q3 2024$-2.83—
Next report no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
AVTX institutional holders
SEC Form 13F
7 of the 45 institutional funds we track reported a AVTX position for the quarter ended 30 Jun 2026 — a combined $84.7M; the latest of those filings landed 14 Aug 2026.